Background: We previously have shown that initial combination therapy with metformin/pioglitazone/exenatide (Triple Therapy) produced greater reduction in A1c than sequential add-on therapy in subjects with new onset of type 2 diabetes (T2D).

Research Design and Methods: The EDICT study is a randomized open-label study in which newly diagnosed drug-naïve T2D subjects with new onset diabetes were randomized to receive Triple Therapy (n=132) or escalating dose of metformin followed by sequential addition of glipizide and then glargine insulin (Conventional Therapy) (n=146) to maintain A1c< 6.5. Here, we report the 6-year follow-up results.

Results: Subjects receiving Triple Therapy experienced a significantly greater reduction in A1c after a mean follow-up of 6 years vs. Conventional Therapy (5.8% vs. 6.7%, p<0.001) (Figure 1). Further, more subjects maintained HbA1c <6.5% in the Triple Therapy group (25%) than in the Conventional Therapy (52%). Progression of carotid IMT (read blindly) was reduced by >50% (P<0.001) in Triple Therapy vs. Insulin Therapy.

Conclusion: The results of this study demonstrate that combination therapy with metformin/pioglitazone/ exenatide in newly diagnosed T2DM patients produces greater and more reduction in A1c than sequential add-on therapy with metformin, sulfonylurea, and basal insulin.
graphic
View largeDownload slide
Disclosure

M. Abdul-Ghani: None. C.L. Puckett: None. C.L. Triplitt: Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Eli Lilly and Company. Consultant; Self; Sanofi, Novo Nordisk Inc. D. Maggs: Stock/Shareholder; Self; Fractyl Laboratories, Inc.. Employee; Self; Fractyl Laboratories, Inc.. Stock/Shareholder; Spouse/Partner; Gelesis. Employee; Spouse/Partner; Gelesis. J.M. Adams: None. E. Cersosimo: Research Support; Self; AstraZeneca, VeroScience, LLC.. Speaker's Bureau; Self; AstraZeneca, Sanofi, Janssen Pharmaceuticals, Inc., Eli Lilly and Company. R.A. DeFronzo: Speaker's Bureau; Self; AstraZeneca, Novo Nordisk Inc.. Advisory Panel; Self; AstraZeneca, Novo Nordisk Inc., Janssen Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Elcelyx Therapeutics, Inc., Intarcia Therapeutics, Inc.. Research Support; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc..

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.